Valneva
was well tolerated in phase safety profile within the expected range for an inactivated vaccine ans | Valneva
Company
Deck Type
IPO
Sector
Industry
Deck date
April 2021
Slide
27 of 41
Related slides by other companies
Ocuphire Pharma
Results
March 2021
summary of positive phase results for eye drops | Ocuphire Pharma
NeuroSense Therapeutics
Investor Presentation
December 2023
phase trial | NeuroSense Therapeutics
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a favorable safety and tolerability profile | DICE Therapeutics
NeuroSense Therapeutics
Investor Presentation
December 2023
strong clinical and commercial potential prime | NeuroSense Therapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io